Results 151 to 160 of about 206,755 (278)
Acta Paediatrica, EarlyView.ABSTRACT Aim This study aimed to explore clinical and laboratory markers of omalizumab response in paediatric and adult chronic spontaneous urticaria (CSU) patients. Methods The study included 32 children and 67 adults with CSU receiving omalizumab, and 29 paediatric and 30 adult healthy controls; associations with treatment response were evaluated ...
Güler Yıldırım Nalbant +14 more
wiley +1 more source
Resolution of celiac disease, IgA deficiency and platelet refractoriness after allogeneic bone marrow transplantation for acute leukemia. [PDF]
Haematologica, 2019 Zandi S +4 more
europepmc +1 more source
Avatrombopag for the salvage treatment of platelet transfusion refractoriness
Background: Platelet transfusion refractoriness (PTR) is a life-threatening and intractable condition in hematological patients. Thrombopoietin receptor agonists such as avatrombopag promote platelet production and modulate immune intolerance.
Jieyu Ye +4 more
core +1 more source
British Journal of Haematology, EarlyView.Summary Ruxolitinib remains first‐line standard of care for symptomatic myelofibrosis, but resistance/intolerance develops in most patients. Three Janus kinase inhibitors (JAKis) have entered the post‐ruxolitinib space via distinct pivotal trials. We systematically searched prospective trials evaluating JAKi in refractory adults with myelofibrosis ...
Andrea Duminuco +8 more
wiley +1 more source
Distinct clinical and genetic characteristics of myelodysplastic syndrome in younger patients
British Journal of Haematology, EarlyView.Summary Myelodysplastic neoplasms (formerly myelodysplastic syndromes, MDS) are heterogeneous clonal haematological malignancies that primarily affect the elderly, though a notable proportion of patients are diagnosed at younger ages. We retrospectively analysed 1437 patients diagnosed or treated at Asan Medical Center between 1989 and 2022, comparing ...
Hyunkyung Park +15 more
wiley +1 more source
British Journal of Haematology, EarlyView.Summary B‐cell maturation antigen‐directed chimeric antigen receptor (CAR) T cells have revolutionized the treatment of relapsed/refractory multiple myeloma. However, no randomized head‐to‐head comparison of idecabtagene vicleucel (ide‐cel) and ciltacabtagene autoleucel (cilta‐cel) is available, and real‐world data suggest differences in efficacy and ...
Irene Strassl +23 more
wiley +1 more source
Immune-mediated platelet refractoriness: Mechanisms, diagnostics, and therapeutic breakthroughs. [PDF]
Transfus MedMa L, Wu L, Xie J.
europepmc +1 more source
British Journal of Haematology, EarlyView.Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa +25 more
wiley +1 more source
IL-8 and sCD40L predict platelet refractoriness and survival of pediatric patients with solid tumors receiving chemotherapy. [PDF]
BMC CancerZhou C +5 more
europepmc +1 more source
British Journal of Haematology, EarlyView.Summary While marginal zone lymphoma (MZL) is generally indolent, outcomes following relapse remain poorly defined. This study utilized the indolent Non Follicular 10 (NF10) prospective database to characterize survival and identify prognostic drivers in patients failing initial systemic therapy. The study analysed 122 patients with relapsed MZL.
Stefano Luminari +28 more
wiley +1 more source